Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Applications Heavily Reliant On Foreign Data Get Positive Signals In US FDA Reviews

Executive Summary

Agency has notably rejected some NDAs that relied solely on Chinese data, but a positive advisory committee for Geron’s proposed anemia treatment imetelstat and approval for BeiGene’s anti-PD-1 antibody Tevimbra suggest that using a lot of foreign data could be OK.

You may also be interested in...



The Dog That Didn’t Bark: ODAC Gives Nod To Three Products Despite Negative FDA Reviews

Oncologic Drugs Advisory Committee was swayed by views of its disease area experts in favorably reporting out Geron’s imetelstat for myelodysplastic syndromes and supplemental applications for the CAR-T products Carvykti and Abecma in earlier lines of multiple myeloma.

BeiGene’s Tevimbra And The End Of The COVID Inspection Era

US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.

With First US Approval, BeiGene’s Tevimbra To Start Small, Work Its Way Up

The FDA approved the PD-1 inhibitor for previously treated esophageal cancer, while BeiGene anticipates decisions on first-line ESCC as well as G/GEJ cancer later in the year.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149989

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel